Recently, Otomo et al 1 developed and validated the so-called 'antiphospholipid score' (aPL-S) by testing multiple aPL and evaluating the aPL-S efficacy for the diagnosis of APS and predictive value for thrombosis. This score was shown to be a useful quantitative index for diagnosing APS and to be valuable as a predictive marker for thrombosis in autoimmune diseases.
In order to independently validate the aPL-S, we applied the proposed score system to a cohort of 211 consecutive patients who attended the Louise Coote Lupus Unit (St Thomas Hospital, London, UK). All the patients fulfilled the 1982 criteria for systemic lupus erythematosus (SLE). 2 Overall, 81 patients fulfilled criteria for APS 3 and 73 patients had a history of thrombosis (48 arterial, 41 venous thrombosis). Out of 144 women who had ever been pregnant, 41 had a history of miscarriages and 34 a history of fetal death. To validate the aPL-S, we adapted the proposed score using our inhouse cut-off values for aPL testing as previously reported or according to the current guidelines, as appropriate.
3-8 aPL profile included anticardiolipin antibodies, lupus anticoagulant by partial thromboplastin time (aPTT -IL-test APTT-SP, Instrumentation Laboratory, Milan, Italy) and dilute Russell viper venom time, anti-β2glycoprotein-I antibody, and antibodies to phosphatidylserine-prothrombin complex. aPL-S was calculated for each patient by adding together the points corresponding to the risk factors as described. 1 Higher values of aPL-S were seen in patients who experienced thrombosis and/or pregnancy loss when compared with those without clinical events (median 17 (0-86) vs 4 (0-31), p<0.001). When analysing clinical subgroups, patients who experienced thrombosis or pregnancy loss showed higher aPL-S compared with those without clinical events (median 18 (0-86) vs 4 (0-27), p<0.001 for thrombosis; 7 (0-69) vs 3 (0-29), p=0.029 for pregnancy loss) (figure 1). In our cohort, when the cut-off level for the aPL-S was defined as 30, as per the original study by Otomo et al, 1 the sensitivity and specificity of the aPL-S were 39% and 95%, respectively, compared with 37% and 96% shown in the Japanese cohort. The positive predictive value of an aPL-S ≥30 was 36%, whereas the negative predictive value was 91%.
We demonstrated that the aPL profile can be successfully quantified by the aPL-S in an independent cohort of SLE patients. The aPL-S correlated with a history of thrombosis or pregnancy loss in our cohort, suggesting that the aPL-S is a suitable quantitative marker of APS.
Figure 1
Antiphospholipid score (aPL-S) in systemic lupus erythematosus (SLE). The aPL-S was calculated according to Otomo et al.1 Data are shown as box plots, where each box represents the 25th to 75th percentiles: lines inside the box represent the median. The whiskers represent the 95% CI. Higher values of aPL-S were seen in patients who experienced thrombosis and/or pregnancy loss (PL) when compared with those without clinical events (p<0.001 by Mann-Whitney U test). When analysed separately, patients who experienced thrombosis or PL showed higher aPL-S when compared with those without clinical events.
